PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE
Clinical safety rating: safe
Strong CYP2C8 inhibitors may increase levels Can cause or exacerbate congestive heart failure and bladder cancer.
Pioglitazone is a thiazolidinedione that acts as an agonist at peroxisome proliferator-activated receptor-gamma (PPAR-γ), increasing insulin sensitivity in adipose tissue, skeletal muscle, and liver. Metformin is a biguanide that decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
| Metabolism | Pioglitazone is extensively metabolized by hydroxylation and oxidation, primarily via CYP2C8 and to a lesser extent CYP3A4. Metformin is excreted unchanged in urine; does not undergo hepatic metabolism. |
| Excretion | Metformin: 90% renal (unchanged), 10% fecal. Pioglitazone: 60-70% renal (metabolites), 20-30% fecal. |
| Half-life | Metformin: 6.2 hours (increased in renal impairment). Pioglitazone: 3-7 hours (parent), 16-24 hours (active metabolites), requiring once-daily dosing. |
| Protein binding | Metformin: negligible (<5% bound). Pioglitazone: >99% bound to serum albumin. |
| Volume of Distribution | Metformin: 1.0 L/kg (distribution into erythrocytes). Pioglitazone: 0.63 L/kg. |
| Bioavailability | Metformin: 50-60% oral. Pioglitazone: >80% oral. |
| Onset of Action | Metformin: 2-3 days (glucose lowering). Pioglitazone: 2-4 weeks (max effect at 6-12 weeks). Both oral. |
| Duration of Action | Metformin: 24 hours (twice daily dosing). Pioglitazone: 24 hours (once daily dosing). |
Initial: 15 mg pioglitazone/500 mg metformin twice daily or 30 mg pioglitazone/500 mg metformin once daily. Titrate gradually based on glycemic response. Maximum: 45 mg pioglitazone/2000 mg metformin per day in divided doses.
| Dosage form | TABLET |
| Renal impairment | Contraindicated if eGFR < 30 mL/min/1.73 m². Not recommended if eGFR 30-45 mL/min/1.73 m². If eGFR falls below 45 mL/min/1.73 m² during therapy, reassess risk vs. benefit and consider reducing metformin dose (maximum 1000 mg/day). |
| Liver impairment | Contraindicated in patients with hepatic impairment (Child-Pugh class A, B, or C) due to pioglitazone and metformin risks. Avoid use; do not initiate. |
| Pediatric use | Safety and efficacy not established in pediatric patients under 18 years. Use is not recommended. |
| Geriatric use | Initiate at lowest dose; avoid if age ≥80 years unless normal renal function confirmed. Monitor renal function frequently due to age-related decline; do not use if eGFR < 45 mL/min/1.73 m². |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Strong CYP2C8 inhibitors may increase levels Can cause or exacerbate congestive heart failure and bladder cancer.
| FDA category | Animal |
| Breastfeeding | Metformin is excreted into human milk with a relative infant dose of approximately 1-2% of maternal weight-adjusted dose; M/P ratio approximately 0.35-0.63. No data on pioglitazone excretion in human milk; animal studies show pioglitazone present in milk. Breastfeeding not recommended due to potential for infant hypoglycemia and lack of safety data. |
| Teratogenic Risk |
■ FDA Black Box Warning
Pioglitazone may cause or exacerbate congestive heart failure. Not recommended in patients with symptomatic heart failure. Discontinue if heart failure develops.
| Common Effects | Weight gain |
| Serious Effects |
Severe renal impairment (eGFR <30 mL/min/1.73 m2); acute or chronic metabolic acidosis (including diabetic ketoacidosis); known hypersensitivity to pioglitazone, metformin, or any component; patients with NYHA Class III/IV heart failure (pioglitazone); active bladder cancer (pioglitazone); hepatic impairment (pioglitazone).
| Precautions | Lactic acidosis (rare but fatal, especially with renal impairment, hypoxia, or alcohol); hepatic effects (pioglitazone); bladder cancer risk (pioglitazone); bone fractures (pioglitazone); hypoglycemia when used with insulin or sulfonylureas; vitamin B12 deficiency (metformin); renal impairment (metformin); hepatic impairment; acute metabolic acidosis; increased cardiovascular mortality risk in select populations. |
Loading safety data…
| Pioglitazone: FDA Pregnancy Category C; not recommended due to potential fetal harm (animal studies show delayed parturition, embryotoxicity). Metformin: FDA Pregnancy Category B; generally considered low risk but no adequate human studies. Use in pregnancy only if benefits outweigh risks; combination therapy lacks human data. |
| Fetal Monitoring | Monitor maternal blood glucose, HbA1c, and renal function (serum creatinine) every 3 months; assess fetal growth by ultrasound per standard high-risk pregnancy protocol; consider fetal echocardiography for potential cardiac effects; monitor for maternal hypoglycemia and lactic acidosis symptoms. |
| Fertility Effects | Pioglitazone may restore ovulation in women with polycystic ovary syndrome (PCOS) due to insulin sensitization; increased risk of unintended pregnancy. Metformin may improve fertility in PCOS patients. No adverse effects on fertility reported; animal studies show no impairment. |